MEK inhibition achieves robust and durable responses in Erdheim–Chester disease

Hemasphere

by Francesco Pegoraro, Félicien Triboulet, Matthias Papo, Francesco Peyronel, Anita Argentieri, Jerome Razanamahery, Ahmed Idbaih, Polyzois Makras, Ofer Shpilberg, Oshrat Hershkovitz-Rokah, Michael Girschikofsky, Matthew Collin, Kristian Bowles, Satyen H. Gohil, Rodothea Amerikanou, Emmanuel Ledoult, Tanguy Le Scornet, Mathilde de Menthon, Etienne Riviere, Xavier Boulu, Henry Dupuy, Achille Aouba, Stanislas Faguer, Xavier Solanich, Elena Sieni, Stéphane Barete, Chiara Bellino, Alessandro Tomelleri, Corrado Campochiaro, Lorenzo Dagna, Zahir Amoura, Jean-François Emile, Fleur Cohen-Aubart, Augusto Vaglio, Julien Haroche
October 6, 2026

Jama Network Open

Physician- and Practice-Level Variation in Clinical Trial Participation Among Patients With Advanced Cancer

Annals Of Internal Medicine: Clinical Cases

Pulmonary Kaposi Sarcoma Presenting With Flame-Shaped Computed Tomography Opacities in Advanced HIV

October 6, 2026

The Analytical Scientist

Machine Learning Alone Won’t Take Vibrational Spectroscopy Into the Clinic

Standardized preprocessing, multicenter datasets, external validation, and interpretable models may matter more than further gains in classification accuracy

September 30, 2026
3 min

MEK Inhibitors Produce Strong, Sustained Responses in Erdheim–Chester Disease

Original Source(s)

MEK inhibition achieves robust and durable responses in Erdheim–Chester disease

Related Content

Physician- and Practice-Level Variation in Clinical Trial Participation Among Patients With Advanced Cancer

Pulmonary Kaposi Sarcoma Presenting With Flame-Shaped Computed Tomography Opacities in Advanced HIV

Machine Learning Alone Won’t Take Vibrational Spectroscopy Into the Clinic